

## RESEARCH ARTICLE

## Role of Plasticity Region Genes and *cagE* gene of *cagPAI* of *Helicobacter pylori* in Development of Gastrointestinal (GI) Diseases

Shokufe Gholizade Tobnagh<sup>1\*</sup>, Seyedeh Zahra Bakhti<sup>1</sup>, Saeid Latifi Navid<sup>1</sup>, Saber Zahri<sup>1</sup>, Fatemeh Sadat Bakhti<sup>2</sup>

### Abstract

**Background:** *Helicobacter pylori* is a Gram-negative, micro aerophilic bacterium in the human stomach that is associated with the development of gastrointestinal ailments such as peptic ulcer (PU) and gastric cancer (GC). In the present study, plasticity region genes (*jhp0940*, *jhp0945* and *jhp0947*) and *cagE* gene of *cagPAI* were assessed independently and in combination for their ability to predict clinical consequences. **Materials and Methods:** A total of 211 strains which were isolated from patients with different gastrointestinal diseases (114 with non-atrophic gastritis, 59 with PU, and 38 with GC) were genotyped by PCR and sequencing. Data were collected and analyzed using SPSS software version 19. Logistic regression models were applied to determine relationships between the plasticity region genes and *cagE* of *H. pylori* and clinical status. **Results:** The *cagE* gene (71.1%) had the highest frequency and *jhp0945* (13.7%) was the least abundant among the genes examined. The *jhp0940* gene was significantly associated with GC ( $P = 0.0007$ ), but not PU. On multiple logistic regression analysis, adjusted for both age and sex, the *jhp0940* genotype was significantly associated with GC (odds ratio, OR = 2.8, 95%CI = 1.1–7.0;  $P = 0.027$ ). The *jhp0940*+/ *jhp0945*+/ *jhp0947*+ genotype was also linked to an increased risk of GC (OR = 50.4, 95%CI = 5.1–500.0;  $P = 0.0008$ ) while no genotype correlation was found with PU in Iran ( $P > 0.05$ ). **Conclusions:** Given the high frequency of *cagE*, this gene could be a suitable marker for the presence of *cagPAI* in Iranian strains. The *jhp0940* genotype could also be a strong predictor of GC in Iran.

**Keywords:** *Helicobacter pylori*- plasticity region genes- *cagE*- gastrointestinal diseases- Iran

*Asian Pac J Cancer Prev*, **18** (1), 43-49

### Introduction

Gastric cancer (GC) is the third cancer-related mortality in the world (Ferlay et al., 2015), so that each year more than one million people are diagnosed with the disease and almost 700,000 of them succumb to it (Parkin et al., 2005). GC is a multifactorial multi-stage disease and *Helicobacter pylori*-specific genotypes, host factors, and environmental co-factors play a remarkable role in its development (Zabaleta 2012).

*H. pylori* infection increases the risk of GC by approximately 10% (Choi et al., 2007). It has been reported that peptic ulcer (PU) was developed in approximately 3-10% of *H. pylori*-infected patients, compared to none of the uninfected patients (Kusters et al., 2006). The studies have shown that variability in virulence factors of *H. pylori* plays a role in bacterial pathogenesis (Figueiredo et al., 2002).

The *cag* pathogenicity island (*cag* PAI) of *H. pylori* is an important virulence factor which contains 27 to 31 genes (Israel and Peek 2001) which encode components

of a bacterial type IV secretion system and inject the CagA protein in the host gastric epithelial cells. It has been shown that strains lacking the *cag* PAI are less virulent compared to strains carrying it (Proenca Modena et al., 2007). The *cagA* (cytotoxin-associated gene A) is one of the virulence genes that is located in *cag* PAI and encodes cancer-causing CagA protein (Nguyen et al., 2008; Hatakeyama 2011; Wroblewski et al., 2010). The *H. pylori* CagA protein is a 120- to 140-kDa protein that is correlated with *H. pylori* pathogenesis (Douraghi et al., 2009b).

Another member of *cag* PAI is called *cagE* (cytotoxin associated gene E) (Censini et al., 1996; Sozzi et al., 2005), and is linked to an increased induction of IL-8 secretion in the gastric epithelial cells (Lima and Rabenhorst 2009). The *cagE* gene along with the *cagA* was introduced as a more accurate biomarker for determining the presence *cag* PAI (Douraghi et al., 2009a). The presence of *cagE* has essential role in the risk to develop severe gastritis, peptic ulcer, and gastric cancer (Chomvarin et al., 2008; Ali et al., 2005; Tan et al., 2005).

<sup>1</sup>Department of Biology, Faculty of Sciences, University of Mohaghegh Ardabili, Ardabil, <sup>2</sup>Department of Biostatistics, Faculty of Public Health, Mazandaran University of Medical Sciences, Sari, Iran. \*For correspondence: gholizades@yahoo.com

A number of *H. pylori* virulence genes are located outside the *cag* PAI, within the plasticity region that is a large chromosomal segment including strain-specific genes transferred from other species (Romo-Gonzalez et al., 2009). Variability in plasticity region genes may be responsible for differences in *H. pylori* pathogenesis (Alm et al., 1999; Alm and Trust 1999). It has been reported that *jhp0940*, *jhp0945*, *jhp0947*, and *jhp0949* in the *H. pylori* strains in Western countries are associated with an increased in IL-8, IL-12, and tumor necrosis factor alpha (TNF- $\alpha$ ) (Romo-Gonzalez et al., 2009; de Jonge et al., 2004; Occhialini et al., 2000; Lehours et al., 2004; Rizwanet al., 2008; Santos et al., 2003; Proenca Modena et al., 2007). The presence, absence, and activity of plasticity region genes may be related to the severity of gastric mucosal injury and increased risk of development of different gastroduodenal diseases. The aim of present study was to examine the relationship between *cagE*, *jhp0940*, *jhp0945*, and *jhp0947* genes and gastroduodenal diseases in Iran.

## Materials and Methods

### Gastric biopsies

Gastric biopsies were obtained from patients with different gastroduodenal diseases referred to the Endoscopy unite in Iran from 2007 to 2014. The total final study population consisted of patients with non-atrophic gastritis (NAG), gastric cancer (GC), and peptic ulcers (PU) (gastric ulcers (GU), duodenal ulcers (DU)).

### Histological examination and classification

Gastric biopsy specimens were taken from the antrum and the corpus and then biopsies were formalin-fixed and embedded in paraffin. For histopathological examination, biopsies were stained with Hematoxylin- eosin, and Giemsa, and Alcian blue-periodic acid Schiff (pH 2.5). By use of Sydney classification system, histopathological evaluations were performed and tumors were classified into intestinal or diffuse adenocarcinoma (Kersulyte et al., 2000).

### *H. pylori* isolation and cultivation

All the tissue specimens taken from both antrum and corpus were cultured and identified on selective Brucella agar plates (Merck, Germany) containing 10% blood, vancomycin (10 mg/mL; Zakaria, Iran), trimethoprim (5 mg/mL; MP Biomedicals, France), and amphotericin B (4 mg/ mL; Bristol-Myers Squibb, USA), under microaerobic conditions. The Cultures were incubated at 37°C for a maximum of 5–7 days. Bacterial isolates were identified as *H. pylori* according to negative Gram staining, morphology, and positive catalase, oxidase, and urease tests, as well as PCR amplification of *H. pylori* 16SrDNA (Lu et al., 2002).

### DNA extraction and PCR amplification

Genomic DNA was extracted from *H. pylori* isolates using the Genomic DNA purification kit (Fermentas, UK) according to the manufacturer's instructions. Extracted DNA was stored at -20°C. Genotyping of *cagE*, *jhp0940*,

*jhp0945*, and *jhp0947* genes were determined by PCR methods and using species-specific primers as shown in Table 1. Negative controls included *Escherichia* DH5a and deionized water. PCR was performed in a total volume of 30 $\mu$ L that contained 3 $\mu$ L of 10X PCR buffer (Cinna Gen, Iran), 1 $\mu$ L of MgCl<sub>2</sub> 200mM, 2 U of Taq DNA polymerase (Cinna Gen, Iran), 0.5 $\mu$ M of each primer, and 25ng of bacterial DNA. The PCR amplification conditions were 96°C for 180 s; then 35 cycles of 96°C for 40 s (denaturation), optimized annealing temperature for each gene (Table 1) for 40 s, and 72°C for 40 s (extension); and finally, 72°C for 7 min (final extension). PCR products were electrophoresed on 1% (w/v) agarose gel and visualized by a UV transilluminator (Figure 1). The band sizes according to gene and allele are listed in Table 1. To confirm, the amplified fragments of each gene from five isolates were purified and sequenced with both forward and reverse primers using BigDye technology on an ABI3700XL DNA sequencer (Applied Biosystems). The BLAST program (<http://www.ncbi.nlm.nih.gov>) was used to match the nucleotide sequences with the published sequences in GenBank.

### Statistical analysis

For statistical analysis, the SPSS version 19 was used. Simple logistic regression analysis by the *Enter* method was used to determine the effect of each pathogenic gene and genotype combinations in gastroduodenal diseases. We used the multiple logistic regression analysis by the Forward Stepwise *Likelihood Ratio (LR)* method to determine which factor(s) has/have a relative influence on GC and other gastric diseases, after controlling for age and sex variables. In all comparative analysis, NAG patients were considered as the control group. A P value of < 0.05 was indicated as statistically significant.

## Results

### Characteristics of patients and genotyping

A total of 214 *H. pylori* strains from patients were obtained and genotyped. In the present study, based on histopathological findings: 114 patients had NAG, 59 had




Figure 1. PCR GEL Electrophoresis Images, A (*jhp0940*), B (*jhp0947*), C (*jhp0945*), D (*cagE*)

Table 1. Primer Sequence and Conditions of PCR Applied in This Study

Genes	Primers	Sequences (5'→3')	Size of PCR products (bp)	Annealing temperature (°C)
<i>16 S rDNA</i>	HP1	GCA ATC AGC GTC AGT AAT GTT C	519	56
	HP2	GCT AAG AGA TCA GCC TAT GTC C		
<i>cagE</i>	Forward	TTGAAAACCTTCAAGGATAGGATAGAGC	508	54
	Reverse	GCCTAGCGTAATATCACCATTACCC		
<i>jhp0940</i>	Forward	GAAATGTCTTATACCAATGG	381	48
	Reverse	CCTAAGTAGTGCATCAAGG		
<i>jhp0945</i>	Forward	ACTCCAGCCAGTATTGTAAA	380-400	48
	Reverse	TTCTTGCGAGTTAGGATTGG		
<i>jhp0947</i>	Forward	GATAATCCTACGCAGAACG	368	48
	Reverse	GCTAAAGTCATTTGGCTGTC		

PU (29/59 with gastric ulcer and 30/59 with duodenal ulcer), and 38 had GC (cardia cancer:14/38, non cardia cancer 23/38 and cardia and non cardia gastric cancer: 1/38; and intestinal type: 20/38 and diffuse type: 18/38); and three patients were excluded from analyses because in their histopathological evaluations no tumor tissue and lymphoma were recognized. As shown in table 2, patients were classified into 2 groups; females: 87/211 and males: 124/211. Also Patients were classified into 2 age groups; including patients with age <55: 133/211 (64.6%) and those with age ≥55: 77/211 (Table 2). The age information for one Patient was not available. The *cagE*, *jhp0940*, *jhp0945*, and *jhp0947* genes were present

in 71.1% (150/211), 45.0% (95/211), 13.7% (29/211), and 49.8% (105/211) of strains, respectively (Table 3).

#### *The Correlation of the H. pylori cagE, jhp0940, jhp0945, and jhp0947 Genotypes with the Risk of GC*

As shown in Table 3, the frequency of the *cagE*+, *jhp0940*+, *jhp0945*+, and *jhp0947*+ genotypes in patients with GC (78.9%, 68.4%, 26.3%, and 68.4%, respectively) was higher than that in those with NAG (73.7%, 36.0%, 14.0%, and 47.4%, respectively). The simple logistic regression analysis showed that only the *jhp0940*+ genotype was significantly associated with the risk of GC; the odds ratio (OR) was 3.858 (95% confidence interval, CI, 1.762-8.447; p = 0.0007, q = 0.0029), while no significant relationship was found between, *cagE*+, *jhp0947*+ and *jhp0945*+ genotypes and the risk of GC (q > 0.05). The major and novel finding in our study was that the *jhp0940*+ genotype one of the most important factors of *H. pylori* associated with gastric cancer in Iran. We used multiple logistic regression analysis to find the most important risk factor(s) related to GC. When the GC was considered as a dependent factor by the multiple logistic regression analysis, only the *jhp0940*+ genotype was remarkably associated with the age- and sex-adjusted risk for GC. The OR was 2.810 (95% CI, 1.126–7.012; p = 0.027). The interesting thing to note is that the simultaneous presence of the *jhp0940* gene with *cagE*, *jhp0947*, and *jhp0945* genes increased virulence strains than the strains that had only *jhp0947* gene. So that simultaneous presence of three genes *jhp0940/jhp0945/jhp0947* of *H. pylori* plasticity region showed very strong relationship with GC (OR = 50.400). According to Table 4, Analysis for genotype combinations with GC risk showed that *jhp0940*+/*jhp0945*+, *jhp0940*+/*jhp0947*+, *jhp0940*+/*cagE*+, *jhp0945*+/*jhp0947*+, *jhp0940*+/*jhp0945*+/*jhp0947*+, *jhp0940*+/*jhp0945*+/*cagE*+, and *jhp0945*+/*jhp0947*+/*cagE*+ were associated with an increased risk of GC. The OR was 8.1 (95% CI, 2.3-29.2; p = 0.001), 6.000 (95% CI, 2.1-16.7; p = 0.0006), 4.4 (95% CI, 1.1-16.6; p = 0.029), 4.8 (95% CI, 1.6-14.9; p = 0.006), 50.4 (95% CI, 5.1-500.0; p = 0.0008), 9.4 (95% CI, 1.4-

Table 2. Characteristics of Patients Enrolled in This Study

Characteristics	Frequency (N)	Percent (%)
Sex		
Male	124/211	58.8
Female	87/211	41.2
Age		
≥55	77 /211	36.5
<55	133/211	63.0
No data	1/211	0.5
Diseases		
NAG	114/211	54.0
PU	59/211	28.0
Gastric ulcer	29/59	49.2
Duodenal ulcer	30/59	50.8
GC	38/211	18.0
Cardia gastric cancer	14/38	36.8
Non cardia gastric cancer	23/38	60.5
Cardia&Non cardia gastric cancer	Jan-38	2.6
Intestinal-type adenocarcinoma	20/38	52.6
Diffuse-type adenocarcinoma	18/38	47.4

NAG, nonatrophic gastritis; PU, peptic ulcer; GU, gastric ulcer; DU, duodenal ulcer; GC, gastric cancer.

Table 3. The Total Frequency of *H. Pylorigenotypes* in Dyspeptic Patients

Genotypes	Frequency N (%)			
	NAG	GC	PU	Total
<i>jhp0940+vs.jhp0940-</i>	41/114 (36.0)	26/38 (68.4)	28/59 (47.5)	95/211 (45.0)
<i>jhp0945+vs.jhp0945-</i>	16/114 (14.0)	10/38 (26.3)	3/59 (5.1)	29/211 (13.7)
<i>jhp0947+vs.jhp0947-</i>	54/114 (47.4)	26/38 (68.4)	25/59 (42.4)	105/211 (49.8)
<i>cagE+vs.cagE-</i>	84/114 (73.7)	30/38 (78.9)	36/59 (61.0)	150/211 (71.1)
<i>jhp0940+ / jhp0945+vs.jhp0940- / jhp0945-</i>	7/72 (9.7)	7/15 (46.7)	3/34 (8.8)	17/121 (14.0)
<i>jhp0940+ / jhp0947+vs.jhp0940- / jhp0947-</i>	18/54 (33.3)	21/28 (75.0)	9/25 (36.0)	48/107 (44.9)
<i>jhp0940+ / cagE+vs.jhp0940- / cagE-</i>	32/52 (61.5)	21/27 (87.5)	22/39 (56.4)	75/115 (65.2)
<i>jhp0945+ / jhp0947+vs.jhp0945- / jhp0947-</i>	9/62 (14.5)	9/20 (45.0)	2/36 (5.6)	20/118 (16.9)
<i>jhp0945+ / cagE+vs.jhp0945- / cagE-</i>	10/32 (31.3)	8/14 (57.1)	2/24 (8.3)	20/70 (28.6)
<i>jhp0947+ / cagE+vs.jhp0947- / cagE-</i>	41/57 (71.9)	19/21 (90.5)	15/28 (53.6)	75/106 (70.8)
<i>jhp0940+ / jhp0945+ / jhp0947+vs.jhp0940- / jhp0945- / jhp0947-</i>	1/37 (2.7)	7/12 (28.3)	2/18 (11.1)	10/67 (14.9)
<i>jhp0940+ / jhp0945+ / cagE +vs.jhp0940- / jhp0945- / cagE-</i>	3/20 (15.0)	5/8 (62.5)	0/17 (0.0)	8/45 (17.8)
<i>jhp0945+ / jhp0947+ / cagE +vs.jhp0945- / jhp0947- / cagE -</i>	6/19 (31.6)	6/7 (85.7)	2/14 (14.3)	14/40 (35.0)

NAG, nonatrophic gastritis; PU, peptic ulcer disease; GC, gastric cancer.

62.2;  $p = 0.019$ ), and 13.0 (95% CI, 1, 268.0-133.3;  $p = 0.030$ ), respectively (Table 4).

*The Correlation of the H. pylori cagE, jhp0940, jhp0945, and jhp0947 Genotypes with the Risk of PU*

The frequency of *cagE+*, *jhp0940+*, *jhp0945+*, and *jhp0947+* genotypes was 61.0%, 47.5%, 5.1%, and 42.4%, respectively in PU patients (table 3). The results of simple logistic regression analysis demonstrated that no genotype was significantly associated with risk of PU ( $P > 0.05$ ).

Also, no significant relationship was found between genotype combinations and PU risk ( $P > 0.05$ ) (Table 4).

**Discussion**

*H. pylori* is a major determinant of different gastrointestinal disease progression. Strain-specific *H. pylori* genes and their different genotypic combinations could determine the clinical outcomes (Ramis et al., 2013). *cag* PAI and plasticity regions are among the low GC

Table 4. Results of Simple Logistic Regression Analysis

Genotypes	Gastric cancer				Peptic ulcer			
	<i>P</i> value	<i>Q</i> value	OR	95%CI	<i>P</i> value	<i>Q</i> value	OR	95%CI
<i>jhp0940+vs.jhp0940-</i>	<b>0.0007a</b>	<b>0.0029</b>	<b>3.858</b>	<b>1.762-8.447</b>	0.144	0.192	1.608	0.849-3.045
<i>jhp0945+vs.jhp0945-</i>	0.086	0.115	2.187	0.894-5.352	0.086	0.176	0.328	0.92-1.176
<i>jhp0947+vs.jhp0947-</i>	0.027	0.0531	2.407	1.107-5.234	0.531	0.531	0.817	0.433-1.540
<i>cagE+vs.cagE-</i>	0.517	0.517	1.339	0.553- 3.243	0.088	0.176	0.559	0.286-1.091
<i>jhp0940+ / jhp0945+vs.jhp0940- / jhp0945-</i>	<b>0.001</b>	<b>0.0039</b>	<b>8.125</b>	<b>2.260-29.205</b>	0.882	0.882	0.899	0.218-3.712
<i>jhp0940+ / jhp0947+vs.jhp0940- / jhp0947-</i>	<b>0.0006</b>	<b>0.0037</b>	<b>6</b>	<b>2.152-16.732</b>	0.816	0.882	1.125	0.417-3.038
<i>jhp0940+ / cagE+vs.jhp0940- / cagE-</i>	<b>0.029</b>	<b>0.0449</b>	<b>4.375</b>	<b>1.154-16.583</b>	0.622	0.882	0.809	0.348-1.881
<i>jhp0945+ / jhp0947+vs.jhp0945- / jhp0947-</i>	<b>0.006</b>	<b>0.0127</b>	<b>4.818</b>	<b>1.557-14.905</b>	0.191	0.383	0.346	0.071-1.701
<i>jhp0945+ / cagE+vs.jhp0945- / cagE-</i>	0.103	0.103	2.933	0.803-10.719	0.052	0.289	0.2	0.039-1.020
<i>jhp0947+ / cagE+vs.jhp0947- / cagE-</i>	0.101	0.103	3.707	0.773-17.773	0.096	0.289	0.45	0.176-1.154
<i>jhp0940+ / jhp0945+ / jhp0947+vs.jhp0940- / jhp0945- / jhp0947-</i>	<b>0.0008</b>	<b>0.0024</b>	<b>50.4</b>	<b>5.080-499.997</b>	0.232	0.394	4.5	0.380-53.288
<i>jhp0940+ / jhp0945+ / cagE +vs.jhp0940- / jhp0945- / cagE-</i>	<b>0.019</b>	<b>0.029</b>	<b>9.444</b>	<b>1.433-62.238</b>	0.999	0.999	0	0.000
<i>jhp0945+ / jhp0947+ / cagE +vs.jhp0945- / jhp0947- / cagE -</i>	<b>0.0307</b>	<b>0.0307</b>	<b>13</b>	<b>1.268-133.285</b>	0.262	0.394	0.361	0.061-2.146

CI, confidence interval; a Bold face data indicate statistically significant results; bFalse discovery rate-adjusted *p*-value.



content regions and more than half of the strain-specific genes are located in plasticity region (Sugimoto et al., 2012; Alm and Trust 1999). The *cag* PAI of *H. pylori* is one of the virulence factors that involves several genes with different functions (Israel and Peek, 2001). The *cagA* and *cagE* genes are the two main virulence factors of *cag* PAI which can be employed as markers of the presence of *cag* PAI (Ramis et al., 2013; Douraghi et al., 2009a). In the current study, 150 (71.1%) isolates out of 211 contained *cagE*. The prevalence of *cagE* in isolates of Iran was higher than that of Turkey (59.3%), Malaysia (59%) and England (62%) but lower than that of Brazil (89.3%) and India (85.4%)(Douraghi et al., 2009a; Erzin et al., 2006; Tiwari et al., 2007). Accordingly, it is suggested that *cagE* would be a more proper marker of the presence of *cag* PAI in the Iranian isolates as it is in isolates of Japan (Maeda et al., 1999), France (Audibert et al., 2001) and Brazil (Ribeiro et al., 2003). Several studies have shown that the *cagE* gene is a more accurate marker of the persistent presence of *cag* PAI compared to other genes (Ikenoue et al., 2001; Sozzi et al., 2005). In the present study, the presence of *cagE* gene in GC and PU isolates showed no meaningful relationship with the mentioned diseases. This finding is in line with Proenca Modena et al. (2007) study in which no meaningful relationship between *cagE* and gastrointestinal diseases were found (Proenca Modena et al., 2007).

More than 50% of *H. pylori* -specific genes are located in the plasticity region (Romo-Gonzalez et al., 2009). Many of them are significantly associated with the risk of *H. pylori*-associated diseases (Sugimoto et al., 2012; de Jonge et al., 2004; Occhialini et al., 2000). Recently *jhp0940*, *jhp0945*, *jhp0947*, and *jhp0949* genes of the plasticity region from Western countries have been reported to be associated with an increased risk of gastroduodenal disease (Romo-Gonzalez et al., 2009; de Jonge et al., 2004; Occhialini et al., 2000; Lehours et al., 2004; Rizwan et al., 2008; Santos et al., 2003; Proenca Modena et al., 2007).

Studies on *jhp0945* gene are very few and far between. In the present study, we observed that the frequency of the *jhp0945*-positive isolates in patients with GC, PU, and NAG was 26.3%, 5.1%, and 14.0%, respectively. There was no significant difference between the frequencies of the *jhp0945*-positive in the isolates from PU or GC and those from NAG ( $P > 0.05$ ). In contrast, Sugimoto et al indicated that in Western isolates, the presence of *jhp0945* was significantly associated with GU (OR= 2.27), DU (OR= 1.86), and GC (OR= 1.92), while in East Asia, the *jhp0945*-positive isolates significantly increased the risk for GU (OR= 2.58) (Ramis et al. 2013). Although *jhp0945* gene had no relationship with PUD or GC on its own, it showed a meaningful relationship with cancer along with the *jhp0940* and *jhp0947* genes.

The *jhp0947* gene, with unknown function has been identified as the most sensitive marker of the plasticity region for *H. pylori* related diseases (Santos et al., 2003; Occhialini et al., 2000) and has been proposed to be associated with severe tissue damage and PU (de Jonge et al. 2004) or development of GC (Santos et al., 2003). The percentage of *jhp0947* gene was reported 58% in a study

in Iran on 143 first-degree relatives GC patients included 68/143 with pan gastritis, 64/143 with antral-predominant gastritis, and 11/143 with corpus-predominant gastritis, with or without atrophy or intestinal metaplasia, and its distribution in 3 groups of gastritis showed no significant difference ( $P > 0.05$ ) (Siavoshi et al., 2011). In this study, the percentage of *jhp0947* gene was 49.8%. The findings showed that *jhp0947* gene had no significant association with gastrointestinal disease ( $P > 0.05$ ) but there was a significant relationship between the simultaneous presence of *jhp0947*, and *jhp0940* genes and an increased risk of GC in Iran ( $P = 0.0006$ ; OR= 6.00). The results of our study conform to previous reports from the Western (Colombia and the United States) and East Asian (South Korea and Japan) countries (Sugimoto et al. 2012). In 2000, Occhialini et al. (Occhialini et al., 2000) demonstrated that the frequency of *jhp0947* in isolates from GC patients (64.7%) was higher than that of gastritis patients (34.6%). Moreover, a study in Brazil (Santos et al., 2003) reported that, in multivariate analysis, the presence of the *jhp0947* was linked to GC (OR= 2.94) and DU (OR=4.84), but not with gastritis. A study on a Dutch population showed a significant relationship between the presence of *jhp0947* and DU, but not with gastritis (de Jonge et al., 2004).

*JHP940* is a protein kinase, which leads to indirectly up regulating phosphorylation of NF- $\kappa$ B p65 at Ser276. It seems that *JHP940* plays a key role in enhancing the gastric inflammatory and inflammation-related different clinical outcomes such as gastric cancer (Hwang et al., 2002; Furuta et al., 2002; El-Omar et al., 2000). Of 211 *H. pylori* isolates from dyspeptic patients, 45.0% carried the *jhp940* gene. The prevalence of *jhp940* gene in this study was similarly distributed among Japanese isolates (40.0%) while the prevalence of *jhp940* was in isolates from Costa Rican, Peruvian, and Spanish were 30.0%, 60.0%, and 5.0% , respectively (Rizwan et al., 2008).

In the present study, *jhp940* gene had no association with PU group ( $P > 0.05$ ). Other studies showed no significant correlation between the presence of *jhp0940* and any gastrointestinal diseases (Santos et al., 2003) or even a preventive effect on GC (Romo-Gonzalez et al., 2009) and PU (Sugimoto et al., 2012). The findings of this study showed that *jhp940* gene had strong relationship with GC group ( $P = 0.0007$ ); the OR in a simple logistic regression model was 3.858. However, in multiple logistic regression analysis, including age, sex, *jhp0940*, *jhp0945*, *jhp0947*, and *cagE* status, when the GC was considered as a dependent factor, the *jhp0940*- positive genotype remained in the final model ( $p = 0.027$ , OR= 2.810; 95% CI=1.126-7.012). We recommend that the *jhp0940* gene of *H. pylori* could be as beneficial biomarker for the risk prediction of GC, but not PU in Iran.

## Acknowledgements

This study was partly supported by a grant from the Research Council of the University of Mohaghegh Ardabili. The supporter had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Competing interest

The authors declare that they have no conflict of interest.

## References

- Ali M, Khan AA, Tiwari SK, et al (2005). Association between cag-pathogenicity island in *Helicobacter pylori* isolates from peptic ulcer, gastric carcinoma, and non-ulcer dyspepsia subjects with histological changes. *World J Gastroenterol*, **11**, 6815-22.
- Alm RA, Ling LS, Moir DT, et al (1999). Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen *Helicobacter pylori*. *Nature*, **397**, 176-80.
- Alm RA, Trust TJ (1999). Analysis of the genetic diversity of *Helicobacter pylori*: the tale of two genomes. *J Mol Med (Berl)*, **77**, 834-46.
- Audibert C, Burucoa C, Janvier B, et al (2001). Implication of the structure of the *Helicobacter pylori* cag pathogenicity island in induction of interleukin-8 secretion. *Infect Immun*, **69**, 1625-9.
- Censini S, Lange C, Xiang Z, et al (1996). cag, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors. *Proc Natl Acad Sci U S A*, **93**, 14648-53.
- Choi KD, Kim N, Lee DH, et al (2007). Analysis of the 3' variable region of the cagA gene of *Helicobacter pylori* isolated in Koreans. *Dig Dis Sci*, **52**, 960-6.
- Chomvarin C, Namwat W, Chaicumpar K, et al (2008). Prevalence of *Helicobacter pylori* vacA, cagA, cagE, iceA and babA2 genotypes in Thai dyspeptic patients. *Int J Infect Dis*, **12**, 30-6.
- de Jonge R, Kuipers EJ, Langeveld SC, et al (2004). The *Helicobacter pylori* plasticity region locus jhp0947-jhp0949 is associated with duodenal ulcer disease and interleukin-12 production in monocyte cells. *FEMS Immunol Med Microbiol*, **41**, 161-7.
- Douraghi M, Mohammadi M, Shirazi M, et al (2009a). Simultaneous detection of cagA and cagE of *Helicobacter pylori* strains recovered from Iranian patients with different gastroduodenal diseases. *Iran J Public Health*, **38**, 98-105.
- Douraghi M, Talebkhan Y, Zeraati H, et al (2009b). Multiple gene status in *Helicobacter pylori* strains and risk of gastric cancer development. *Digestion*, **80**, 200-7.
- El-Omar EM, Carrington M, Chow WH, et al (2000). Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature*, **404**, 398-402.
- Erzin Y, Koksal V, Altun S, et al (2006). Prevalence of *Helicobacter pylori* vacA, cagA, cagE, iceA, babA2 genotypes and correlation with clinical outcome in Turkish patients with dyspepsia. *Helicobacter*, **11**, 574-80.
- Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, **136**, 359-86.
- Figueiredo C, Machado JC, Pharoah P, et al (2002). *Helicobacter pylori* and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. *J Natl Cancer Inst*, **94**, 1680-7.
- Furuta T, El-Omar EM, Xiao F, et al (2002). Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. *Gastroenterology*, **123**, 92-105.
- Hatakeyama M (2011). Anthropological and clinical implications for the structural diversity of the *Helicobacter pylori* CagA oncoprotein. *Cancer Sci*, **102**, 36-43.
- Hwang IR, Kodama T, Kikuchi S, et al (2002). Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in *Helicobacter pylori* infection. *Gastroenterology*, **123**, 1793-803.
- Ikenoue T, Maeda S, Ogura K, et al (2001). Determination of *Helicobacter pylori* virulence by simple gene analysis of the cag pathogenicity island. *Clin Diagn Lab Immunol*, **8**, 181-6.
- Israel DA, Peek RM (2001). Pathogenesis of *Helicobacter pylori*-induced gastric inflammation. *Aliment Pharmacol Ther*, **15**, 1271-90.
- Kersulyte D, Mukhopadhyay AK, Velapatino B, et al (2000). Differences in genotypes of *Helicobacter pylori* from different human populations. *J Bacteriol*, **182**, 3210-8.
- Kusters JG, van Vliet AH, Kuipers EJ (2006). Pathogenesis of *Helicobacter pylori* infection. *Clin Microbiol Rev*, **19**, 449-90.
- Lehours P, Dupouy S, Bergey B, et al (2004). Identification of a genetic marker of *Helicobacter pylori* strains involved in gastric extranodal marginal zone B cell lymphoma of the MALT-type. *Gut*, **53**, 931-7.
- Lima VP, Rabenhorst SHB (2009). Genes associados à virulência de *Helicobacter pylori*. *Revista Brasileira de Cancerologia*, **55**, 389-96.
- Lu Y, Redlinger TE, Avitia R, et al (2002). Isolation and genotyping of *Helicobacter pylori* from untreated municipal wastewater. *Appl Environ Microbiol*, **68**, 1436-9.
- Maeda S, Yoshida H, Ikenoue T (1999). Structure of cag pathogenicity island in Japanese *Helicobacter pylori* isolates. *Gut*, **44**, 336-41.
- Nguyen LT, Uchida T, Murakami K, et al (2008). *Helicobacter pylori* virulence and the diversity of gastric cancer in Asia. *J Med Microbiol*, **57**, 1445-53.
- Occhialini A, Marais A, Alm R, et al (2000). Distribution of open reading frames of plasticity region of strain J99 in *Helicobacter pylori* strains isolated from gastric carcinoma and gastritis patients in Costa Rica. *Infect Immun*, **68**, 6240-9.
- Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. *CA Cancer J Clin*, **55**, 74-108.
- Proenca Modena JL, Lopes Sales AI, Olszanski Acrani G, et al (2007). Association between *Helicobacter pylori* genotypes and gastric disorders in relation to the cag pathogenicity island. *Diagn Microbiol Infect Dis*, **59**, 7-16.
- Ramis IB, Vianna JS, Silva Junior LV, et al (2013). cagE as a biomarker of the pathogenicity of *Helicobacter pylori*. *Rev Soc Bras Med Trop*, **46**, 185-9.
- Ribeiro ML, Godoy AP, Benvengo YH, et al (2003). Clinical relevance of the cagA, vacA and iceA genotypes of *Helicobacter pylori* in Brazilian clinical isolates. *FEMS Immunol Med Microbiol*, **36**, 181-5.
- Rizwan M, Alvi A, Ahmed N (2008). Novel protein antigen (JHP940) from the genomic plasticity region of *Helicobacter pylori* induces tumor necrosis factor alpha and interleukin-8 secretion by human macrophages. *J Bacteriol*, **190**, 1146-51.
- Romo-Gonzalez C, Salama NR, Burgeno-Ferreira J, et al (2009). Differences in genome content among *Helicobacter pylori* isolates from patients with gastritis, duodenal ulcer, or gastric cancer reveal novel disease-associated genes. *Infect Immun*, **77**, 2201-11.
- Santos A, Queiroz DM, Menard A, et al (2003). New pathogenicity marker found in the plasticity region of the *Helicobacter pylori* genome. *J Clin Microbiol*, **41**, 1651-5.
- Siavoshi F, Asgharzadeh A, Ghadiri H, et al (2011). *Helicobacter pylori* genotypes and types of gastritis in first-degree relatives of gastric cancer patients. *Int J Med Microbiol*, **301**, 506-12.
- Sozzi M, Tomasini ML, Vindigni C, et al (2005). Heterogeneity of cag genotypes and clinical outcome of *Helicobacter pylori* infection. *J Lab Clin Med*, **146**, 262-70.

- Sugimoto M, Watada M, Jung SW, et al (2012). Role of Helicobacter pylori plasticity region genes in development of gastroduodenal diseases. *J Clin Microbiol*, **50**, 441-8.
- Tan HJ, Rizal AM, Rosmadi MY, et al (2005). Distribution of Helicobacter pylori cagA, cagE and vacA in different ethnic groups in Kuala Lumpur, Malaysia. *J Gastroenterol Hepatol*, **20**, 589-94.
- Tiwari SK, Khan AA, Manoj G, et al(2007). A simple multiplex PCR assay for diagnosing virulent Helicobacter pylori infection in human gastric biopsy specimens from subjects with gastric carcinoma and other gastro-duodenal diseases. *J Appl Microbiol*, **103**, 2353-60.
- Wroblewski LE, Peek RM Jr, Wilson KT (2010). Helicobacter pylori and gastric cancer: factors that modulate disease risk. *Clin Microbiol Rev*, **23**, 713-39.
- Zabaleta J (2012). Multifactorial etiology of gastric cancer. *Methods Mol Biol*, **863**, 411-35.